Literature DB >> 19249227

Second and third line treatment in non-small cell lung cancer.

Adolfo Favaretto1, Giulia Pasello, Cristina Magro, Clorinda Schettino, Cesare Gridelli.   

Abstract

Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related deaths worldwide, and the advances in second and third line treatment have led to prognostic improvements in the latest years. Besides the two cytotoxic agents, docetaxel and pemetrexed, approved in NSCLC second line treatment, a new class of drugs against specific molecular targets seems to be an alternative to conventional treatment. Many trials are ongoing to assess the activity of new drugs, alone or in association, and new combinations of third-generation chemotherapeutic agents.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19249227     DOI： 10.1016/j.critrevonc.2009.01.009

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN： 1040-8428            Impact factor:   6.312


  4 in total

1.  High response of second-line chemotherapy with pemetrexed or gemcitabine combined with carboplatin in patients with non-small-cell lung cancer experiencing progression following 6 months after concluding platinum-based chemotherapy.

Authors:  Oscar Arrieta; Cynthia Villarreal-Garza; Digna Pachuca; Rosa M Michel Ortega; Luis Martinez-Barrera; Diana Flores-Estrada; Alma Astorga
Journal:  Med Oncol       Date:  2010-01-05       Impact factor: 3.064

Review 2.  Effectiveness and safety of pemetrexed-based doublet versus pemetrexed alone as second-line treatment for advanced non-small-cell lung cancer: a systematic review and meta-analysis.

Authors:  Wei-Xiang Qi; Li-Na Tang; Ai-Na He; Zan Shen; Yang Yao
Journal:  J Cancer Res Clin Oncol       Date:  2012-01-19       Impact factor: 4.553

3.  Gambogic acid potentiates gemcitabine induced anticancer activity in non-small cell lung cancer.

Authors:  Elham Hatami; Prashanth K B Nagesh; Meena Jaggi; Subhash C Chauhan; Murali M Yallapu
Journal:  Eur J Pharmacol       Date:  2020-08-14       Impact factor: 4.432

4.  Differences in the efficacy of S-1 monotherapy according to histological type in pretreated patients with advanced non-small cell lung cancer.

Authors:  Yasushi Hisamatsu; Haruyasu Murakami; Hiroaki Akamatsu; Madoka Kimura; Keita Mori; Hisao Imai; Akira Ono; Takehito Shukuya; Tetsuhiko Taira; Hirotsugu Kenmotsu; Tateaki Naito; Masahiro Endo; Takashi Nakajima; Toshiaki Takahashi; Nobuyuki Yamamoto
Journal:  Thorac Cancer       Date:  2014-03-03       Impact factor: 3.500
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.